Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1988 3
1989 1
1990 3
1991 4
1992 5
1993 3
1994 4
1995 5
1997 4
1998 6
1999 8
2000 9
2001 10
2002 10
2003 5
2004 11
2005 9
2006 19
2007 15
2008 12
2009 7
2010 6
2011 18
2012 24
2013 22
2014 34
2015 27
2016 28
2017 34
2018 37
2019 25
2020 26
2021 10
Text availability
Article attribute
Article type
Publication date

Search Results

400 results
Results by year
Filters applied: . Clear all
Page 1
Cholangiocarcinoma.
Razumilava N, Gores GJ. Razumilava N, et al. Lancet. 2014 Jun 21;383(9935):2168-79. doi: 10.1016/S0140-6736(13)61903-0. Epub 2014 Feb 26. Lancet. 2014. PMID: 24581682 Free PMC article. Review.
Mixed hepatocellular cholangiocarcinomas have emerged as a distinct subtype of primary liver cancer. Clinicians need to be aware of intrahepatic cholangiocarcinomas arising in cirrhosis and properly assess liver masses in this setting for cholangiocarcinoma. ...
Mixed hepatocellular cholangiocarcinomas have emerged as a distinct subtype of primary liver cancer. Clinicians need to be aware of i …
Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Banales JM, et al. Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. doi: 10.1038/s41575-020-0310-z. Epub 2020 Jun 30. Nat Rev Gastroenterol Hepatol. 2020. PMID: 32606456 Free PMC article. Review.
The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive app …
The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their …
Pathogenesis, diagnosis, and management of cholangiocarcinoma.
Rizvi S, Gores GJ. Rizvi S, et al. Gastroenterology. 2013 Dec;145(6):1215-29. doi: 10.1053/j.gastro.2013.10.013. Epub 2013 Oct 15. Gastroenterology. 2013. PMID: 24140396 Free PMC article. Review.
Furthermore, CCAs are surrounded by a dense stroma that contains many cancer-associated fibroblasts, which promotes their progression. We have gained a better understanding of the imaging characteristics of iCCAs and have developed advanced cytologic techniques to detect p …
Furthermore, CCAs are surrounded by a dense stroma that contains many cancer-associated fibroblasts, which promotes their progression …
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Abou-Alfa GK, et al. Lancet Oncol. 2020 Jun;21(6):796-807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13. Lancet Oncol. 2020. PMID: 32416072 Free PMC article. Clinical Trial.
BACKGROUND: Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with intrahepatic cholangiocarcinoma, a relatively uncommon cancer with a poor clinical outcome. The aim of this international phase 3 study was to assess the efficacy and safety …
BACKGROUND: Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with intrahepatic cholangiocarcinoma, a relat …
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Shroff RT, et al. JAMA Oncol. 2019 Jun 1;5(6):824-830. doi: 10.1001/jamaoncol.2019.0270. JAMA Oncol. 2019. PMID: 30998813 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the association between progression-free survival and the addition of nanoparticle albumin-bound (nab)-paclitaxel to gemcitabine-cisplatin for the treatment of patients with advanced biliary tract cancer. DESIGN, SETTING, AND PARTICIPANTS: This open- …
OBJECTIVE: To evaluate the association between progression-free survival and the addition of nanoparticle albumin-bound (nab)-paclitaxel to …
Targeting cholangiocarcinoma.
Mertens JC, Rizvi S, Gores GJ. Mertens JC, et al. Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1454-1460. doi: 10.1016/j.bbadis.2017.08.027. Epub 2017 Aug 24. Biochim Biophys Acta Mol Basis Dis. 2018. PMID: 28844952 Free PMC article. Review.
However, The Tumor Genome Atlas (TCGA) marker analysis of CCA also highlights the tremendous molecular heterogeneity of this cancer rendering comprehensive employment of targeted therapies challenging. CCA also display a rich tumor microenvironment which may be easier to t …
However, The Tumor Genome Atlas (TCGA) marker analysis of CCA also highlights the tremendous molecular heterogeneity of this cancer r …
Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.
Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wei Wang X, Zhu AX. Sirica AE, et al. Hepatology. 2019 Apr;69(4):1803-1815. doi: 10.1002/hep.30289. Epub 2019 Mar 25. Hepatology. 2019. PMID: 30251463 Free PMC article. Review.
The significant increase in mortality rates from this primary hepatobiliary cancer, particularly over the past decade, has coincided with a rapidly growing interest among clinicians, investigators, and patient advocates to seek greater mechanistic insights and more effecti …
The significant increase in mortality rates from this primary hepatobiliary cancer, particularly over the past decade, has coincided …
Hilar cholangiocarcinoma: expert consensus statement.
Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Mansour JC, et al. HPB (Oxford). 2015 Aug;17(8):691-9. doi: 10.1111/hpb.12450. HPB (Oxford). 2015. PMID: 26172136 Free PMC article.
The ideal treatment for suitable patients with resectable hilar malignancy is resection of the intra- and extrahepatic bile ducts, as well as resection of the involved ipsilateral liver. ...
The ideal treatment for suitable patients with resectable hilar malignancy is resection of the intra- and extrahepatic bile ducts, as …
400 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page